T HE PAST SEVERAL YEARS have witnessed the elucidation of the molecular basis of a number of clinically relevant human platelet alloantigen systems. It would appear from the data collected from a number of different laboratories that the existence ofall ofthe offending epitopes seems to be due to the presence of single amino acid substitutions within the polypeptide chain of the glycoprotein (GP) that bears the alloantigenic epitope."' Biochemical and immunochemical characterization of allele-specific recombinant forms of these platelet membrane GPs has shown, in those cases thus far examined, that these amino acid dimorphisms control both the formation as well as the expression of the alloantigenic determinant^,^,' although posttranslational modifications (ie, glycosylation) of the polypeptide chain may, in some instances, play a secondary role in the formation of the antibody-combining site on the target Historically, new alloantisera identified by the obligatory serologic studies, as well as the antigen system that they define, have been assigned a name based on that of the patient from which an alloantiserum was derived. As might be expected, the presence of multiple independently discovered sera bearing different patient signatures (ie, Zw and P I A , Bak and Lek, Pen and Yuk, Ca and Tu, Br and Hc, to name a few) began to confuse the literature to the point of being understandable only to the af~cionados in the field of platelet immunology, which had themselves developed a certain degree of controversy regarding the priority of antigen system names.
To overcome these difficulties, von dem Borne and Deunique antibody specificity was assigned a human platelet alloantigen (HPA) number. The HPA nomenclature system had as its laudable purpose consolidation and replacement of the somewhat antiquated system described above. Thus, the PIA (Zw) alloantigen system was assigned the HPA-I antigen designation, with its two serologically defined forms known as HPA-1 a and HPA-1 b, the two allelic forms of the KO (Sib) system were designated HPA-2a and HPA-2b, and so on. Unfortunately, this nomenclature system was conceived just before the discovery ofthe actual molecular basis of platelet membrane GP polymorphisms, and, as will be discussed below, does not seem to be capable, in its present form, of serving the nomenclature needs while remaining scientifically accurate at the same time. For illustration purposes, I will discuss the HPA nomenclature of human platelet membrane GPIIIa, because it currently represents the "worst case scenario," having 6 different allelic variants that have been characterized at the molecular l e~e l . "~~~~~ Figure I shows the known polymorphic forms of the GPIIIa molecule in the human gene pool, together with their gene frequencies among Caucasians and their serologic and HPA nomenclature designations. The first 5 lines (boxed together) portray the high-frequency allelic form for each of the "alloantigen systems" thus far attributed to serologically recognized polymorphisms, whereas the second 5 lines illustrate the low-frequency alleles, with the polymorphic amino acid responsible for the formation of the alloantigenic epitope boxed. Close examination of the top half of Fig 1 reveals the striking finding that the HPA-la, HPA-4a, HPA-7aY HPA-6a, and HPA-8a antigens are actually 5 different names for the same identical molecular species, ie, a single GPIIIa allele with a gene frequency of 0.85 having the phenotype of GPIIIaFrom a molecular genetic point of view, it is clearly unacceptable that the same allelic form, having a defined composition and a single gene frequency, be given different names that depend only on the minor variant with which it is paired. This differs significantly from other commonly used nomenclature systems, such as that used for histocompatibility (HLA) antigens, in which each locus would have a designation (ie, the class I HLA-A locus or the class I1 HLA-DR locus), with each allelic form or molecular variant given a number (ie, HLA-A2, HLA DR1).
A second feature revealed by comparison of the low-frequency allelic forms of GPIIIa is that each of them differ by a single amino acid from the molecular species represented by the top 5 lines of Fig 1 For l) , and that all other platelet GP alleles have retained their current HPA designation. One potential burden is the necessityfor someone to discover a new polymorphic platelet membrane GP so that we can have an HPA-4 alloantigen system again.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From of the molecular variants have arisen by point mutations of the same "wild-type" GPIIIa allele. While it is theoretically possible to have, for instance, a Gln,43 (Pen') amino acid mutation of a Pro33 (PIA2) allelic form, it is extremely unlikely that any of us will ever encounter a "double mutant" alloantigenic molecular form of GPIIIa. Therefore, these can be discounted from a practical point of view.
With these realizations in hand, how should we structure a genetically correct nomenclature system for platelet alloantigens that will accommodate current knowledge of their molecular etiology, provide for future discoveries of minor variants (certainly most or all of the major antigenic forms have now been described, with the possible exception of those that may occur with higher frequency in non-Caucasian populations), and still be of general utility to clinicians? Certainly, the system based on patient names is nondescriptive, uninformative, and inappropriate.
One possibility might be to adapt the nomenclature system already in use by investigators in the platelet membrane GP field, thereby allowing them to comprehend what we are talking about in the field of platelet immunobiology (they have no idea what HPA-4b is!). A permutation of this might be to use the integrin nomenclature where applicable to that subset of platelet membrane GPs. In either system one could simply number the alleles I , 2, 3, and so on based on their gene frequencies or order of discovery. A potential nomenclature system incorporating these ideas is illustrated in Fig  2. As shown at the top of Fig 2, the two forms of GPIa that comprise the Br (HPA-5) alloantigen systemI3 are simply named GPIa-0 I and 02. If other allelic forms are discovered in the future, they would, upon confirmation by appropriate workshops, be named 03,04, and so on. The same reasoning holds for the molecular variants that define the other platelet antigen systems, and would be particularly helpful for the 6 allelic forms of GPIIIa that currently comprise HPAs l , 4, 6, 7, and 8. Instead of having to remember S different, artificially separated antigen systems, one merely has to know that there are currently 6 forms of GPIIIa (integrin p3) and that we have named them I through 6. This then would truly define an antigen system, much the same as the HLA system currently has 4 l recognized allelic forms of the protein encoded by its A locus, 6 1 alleles of HLA-B, and so forth.
However, this system is not without its drawbacks. Although 01 and 02 are easy enough to deal with for those antigen systems having only 2 allelic forms, it might be difficult to remember the precise difference between GPIIIa-04 and GPIIIa-06. To overcome this difficulty, a nomenclature system that incorporates the actual polymorphism into the name of the allele, as illustrated in Fig 3, might offer several advan- tages. The most frequent allele would retain the GP name only, whereas molecular variants would be identified by the (or those) amino acids that differ from the wild-type form. Thus, we would have GPIIb and Ser843GPIIb, GPIa and LysSOSGPIa, and so on. This represents, in my opinion, the most descriptive, scientifically accurate nomenclature, although it is still nearly impossible to remember by rote, and could pose a problem in communication with nonacademically oriented "physicians in the field." A copy of Fig 3, however, is posted in my laboratory for everyday reference.
Perhaps a useful compromise between the old and the new might be the adoption of a hybrid nomenclature that incorporates some of the features of each of the possibilities described above. Since HPAs 2 (KO), 3 (Bak), and 5 (Br) represent scientifically accurate alloantigen systems of a single platelet membrane GP, the molecular variants in each of these could retain their current HPA allelic names of HPA-2a and 2b. HPA-3a and 3b, and HPA-Sa and 5b. We would collapse all the other inadvertently misnamed allelic forms of GPIIIa into the HPA-1 alloantigen system, and designate them HPA-I a, I b, 1 c, 1 d, le, and If, representing the serologically defined PIA2. Pen'.
MO", Ca", and Sf allelic forms of the GPIIIa molecule, respectively. Such a nomenclature system, illustrated in Fig 4, retains continuity with the increasingly popular, and only 3-year-old, HPA system of von dem Borne and Decary, represents a genetically correct way of naming allelic forms of individual membrane GPs, and can easily accommodate future additions to what is certainly going to be a growing list of minor molecular variants that will be identified in coming years as molecular techniques are adopted by more serologic testing centers. The only drawback to this nomenclature system relative to that of Fig 3 is its lack of description of the molecular variation underlying the formation of the alloantigenic epitope. The nomenclature system proposed in Fig 4, however, could be viewed as a midcourse correction to an already established system. Regardless of which of the nomenclature systems (if any) outlined above eventually becomes adopted, it will be important that the way in which human platelet alloantigens are designated be both scientifically accurate and genetically correct, and of general utility to both scientists and clinicians alike.
S:
Demonstration of the heterogeneity of epitopes of the plateletspecific alloantigen, Baka. Br J Haematol76: 395, 1990 l l. von dem Borne AE, Decary F ICSH/ISBT Working Party on platelet serology. Nomenclature of platelet-specific antigens. Vox Sang 58: 176, 1990 12. von dem Borne AE, Decary F Nomenclature of platelet-specific antigens. Hum Immunol29: I , 1990
13. Santoso S, Kalb R, Walka M, Kiefel V, Mueller-Eckhardt C, Newman PJ: The human platelet alloantigens Br" and BP are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit a2). J Clin Invest 92: 2427, 1993 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
